IL4 and allergic asthma: A similar effect on the reduction of airway inflammation in the same mouse model of allergic asthma was achieved by oral administration of Bacillus subtilis (B. subtilis) spores with surface expression of HP-NAP fused to the CTB, a mucosal adjuvant inducing antigen tolerance [69] and the administration of the plasmid to express the fusion protein of HP-NAP and soluble IL-4 receptor (sIL-4R), a decoy receptor to bind IL-4 released by Th2 cells and eosinophils [70].